Surgery may provide more durable long-term outcomes for others, especially in cases of severe obesity or obesity-related conditions such as type 2 diabetes, sleep apnoea or cardiovascular risk
We continue to stay abreast of ongoing research to ensure our patients benefit from the latest insights into the comparative benefits and risks of these two GLP-1 receptor agonists in the management of type 2 diabetes
Approval status Neither CJC-1295 (No DAC) nor Ipamorelin is an approved medicine - neither is on the Australian Register of Therapeutic Goods, and the TGA has not evaluated either for safety, quality or effectiveness
One reviewer noted, "After a month, my acne scars faded noticeably, and my skin feels smoother." Another shared, "It's gentle yet effective for evening out tone without dryness." From online forums, consistency is highlighted: "Pairing it with vitamin C boosted results." Some mention minimal changes if expectations are unrealistic, emphasizing patience
Dosing and benefit summary Many of ALAs studied effects appear to be dose-dependent, with stronger responses seen at higher doses